arrow
A

Andrea Gallina

Erasmus MC Cancer Institute
H指数:67
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TRIMODAL THERAPY VERSUS RADICAL CYSTECTOMY IN MUSCLE-INVASIVE BLADDER CANCER: THE OVERLOOKED INFLUENCE OF INFORMATIVE CENSORING. A SYSTEMATIC REVIEW AND META-ANALYSIS

肌层浸润性膀胱癌的三联疗法与根治性膀胱切除术的比较:信息性删失被忽视的影响。系统评价与Meta分析

2026-05-010
PRE
ASSESSING THE OPTIMAL ANDROGEN DEPRIVATION THERAPY DURATION IN PATIENTS WITH PERSISTENTLY ELEVATED PSA AFTER RADICAL PROSTATECTOMY UNDERGOING SALVAGE RADIATION THERAPY

评估根治性前列腺切除术后持续性升高PSA且接受挽救性放疗患者的最佳雄激素剥夺治疗持续时间

2026-05-010
PRE
THE EVOLVING MANAGEMENT OF PN1 PROSTATE CANCER: TEMPORAL TRENDS IN ADJUVANT RADIOTHERAPY VERSUS OBSERVATION ± SALVAGE RT OVER 20 YEARS AT A TERTIARY REFERRAL CENTRE

前列腺癌pN1分期的演变管理:一家三级转诊中心20年来辅助放疗与观察±挽救性放疗的时间趋势

2026-05-010
PRE
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer

多学科瑞士共识:肌层浸润性膀胱癌根治性膀胱切除及三联治疗后随访建议

2026-01-010
PRE
Addressing Uneven Treatment Discontinuation Rate in the Chemotherapy Arm of the EV-302 Phase 3 Randomized Clinical Trial: Implications for Outcome Interpretation

解决EV-302 III期随机临床试验化疗组治疗中断率不均衡的问题:对结局解释的影响

2025-12-010
PRE
Trimodal treatment vs radical cystectomy for muscle-invasive bladder cancer: The neglected impact of informative censoring. A systematic review and meta-analysis

肌层浸润性膀胱癌的三联疗法与根治性膀胱切除术:信息性删失被忽视的影响。系统评价与荟萃分析

2025-06-200
PRE
THE IMPACT OF HISTOLOGY AND TYPE OF ENERGY USED ON ONCOLOGICAL OUTCOMES AFTER LOCAL TUMOR ABLATION OF SMALL RENAL MASSES
2024-05-010
PRE
Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer
2024-05-011
OA
Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial
2023-01-012
PRE
Robot-Assisted, Laparoscopic, and Open Radical Cystectomy: Pre-Operative Data of 1400 Patients From The Italian Radical Cystectomy Registry
2022-05-057
OAAI
Reply to Nicolas Mottet, Olivier Rouviere, and Theodorus H. van der Kwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? Eur Urol Oncol. In press Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited
2022-04-011
PREAI
Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection
2022-03-016
OAAI
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
2021-12-0116
PREAI